Panacea Biotec has received significant updates to its UNICEF contract for supplying pentavalent vaccine Easyfive-TT, as well as new awards for pentavalent and polio vaccines. The contract updates include increased order volumes for 2026 and 2027, totaling $8.93 million (₹80.00 crores). Additionally, the company secured a long-term agreement to supply bivalent oral polio vaccine (bOPV) from April 2026 to March 2030. These developments strengthen Panacea Biotec's position as a key supplier of WHO pre-qualified vaccines for global immunization programs.
Panacea Biotec Secures $8.9 Million Additional Vaccine Orders from UNICEF
